Clinical Trials | January 06, 2026
BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Subscribe To Our Newsletter & Stay Updated
